Biopharmaceutical companies in need of chemicals under stringent quality control now have the option to utilize a new manufacturing and distribution hub established by a biopharmaceutical maker. This firm serves approximately 300,000 biopharmaceutical customers worldwide and provides them with chemicals and equipment essential for the development of biopharmaceutical products, including drugs and vaccines.
The choice to invest in the Singapore hub stems from the firm’s intention to cater to the robust local biopharmaceutical market while capitalizing on its central location to effectively serve customers across the AMEA region.
With the launch of the Singapore Manufacturing and Distribution Hub, the firm aims to enhance its regional capabilities and build upon its legacy of meeting the evolving needs of customers, demonstrating a strong commitment to advancing life-changing science.
Spanning the hub are a fully equipped quality control laboratory and two warehouses, which can accommodate more than 25,000 stock-keeping units of chemicals, consumables, and equipment. These facilities enable the hub to drive innovation and address immediate challenges within the biopharma industry in the AMEA region.
By leveraging the new hub, customers can expect faster turnaround times and increased supply chain resiliency. It also ensures expanded capabilities in compliance with current good manufacturing practices and stringent quality control measures to meet the needs of customers.
This expansion of the biopharmaceutical firm’s Singapore hub bolsters the supply of crucial materials and services required by biopharma manufacturers in both Singapore and the wider region. It contributes to the strengthening of supply chain resilience for businesses and enhances the competitiveness of Singapore’s biomedical sciences industry—a vital component of the country’s thriving manufacturing sector.
